Posaconazole therapy of disseminated phaeohyphomycosis in a murine model.
about
Melanized fungi in human diseaseBlack yeasts and their filamentous relatives: principles of pathogenesis and host defenseCytolocalization of the class V chitin synthase in the yeast, hyphal and sclerotic morphotypes of Wangiella (Exophiala) dermatitidisAntifungal susceptibility patterns of opportunistic fungi in the genera Verruconis and Ochroconis.Mycetoma medical therapy.Posaconazole: clinical pharmacology and potential for management of fungal infections.Therapy of infections caused by dematiaceous fungi.Molecular and Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry-Based Characterization of Clinically Significant Melanized Fungi in India.Antifungal efficacy and pharmacodynamics of posaconazole in experimental models of invasive fungal infections.Dematiaceous fungi.CNS pharmacokinetics of antifungal agents.Posaconazole's impact on prophylaxis and treatment of invasive fungal infections: an update.What can we learn and what do we need to know amidst the iatrogenic outbreak of Exserohilum rostratum meningitis?Use of posaconazole in the treatment of invasive fungal infections.Mycoses of implantation in Latin America: an overview of epidemiology, clinical manifestations, diagnosis and treatment.Efficacy of caspofungin and posaconazole in a murine model of disseminated Exophiala infection.Reflections on the approach to treatment of a mycologic disaster.Posaconazole: a next-generation triazole antifungal.Antifungal therapy in an athymic murine model of chromoblastomycosis by Fonsecaea pedrosoi.Fungal meningoencephalitis caused by Alternaria: a clinical case.Murine model of a disseminated infection by the novel fungus Fonsecaea monophora and successful treatment with posaconazole.Posaconazole as salvage therapy in patients with chronic granulomatous disease and invasive filamentous fungal infection.A rare case of subcutaneous phaeohyphomycosis caused by a Rhytidhysteron species: a clinico-therapeutic experience.
P2860
Q24633163-1D4155AE-D4B0-4828-9411-07AF117DA5FCQ27028032-00064376-6E8A-4BDC-A49B-7C0AE7277C28Q30373183-598D879B-AC4B-40EF-B1D0-FFB41678A9FFQ35136368-386332A8-9101-4F36-9635-6C6A6F187CB5Q35351362-57DD9669-1085-46FF-805C-45F7B4FFCD46Q36233491-B08B3FC6-2C48-4803-BDEE-64C8E5E7DA1AQ36233517-DCAD3FCB-36C1-4BEC-B5A3-19E57C46A579Q36253313-5A00D2C7-D060-481D-BBDF-F4581B806494Q36589297-709763BA-1BB1-4F15-8432-484679B86C1EQ36738130-C236948B-2520-47DB-B264-4397417BB42EQ36909333-960E14CE-522D-48C7-AE1E-97CCBA649484Q37404840-115FC6E3-3A3E-467B-AE01-8FE1E9D3E63DQ37463387-5DAFFB57-4640-489F-B70C-B06718EBC98AQ37810083-F39415FF-0DE4-435B-AD10-F04C5697DEA0Q37815477-B739EE40-DA6F-4690-801B-36E455778230Q38504361-289BA10E-64DF-4386-B29D-70022710F149Q39767419-437C1B62-7F3A-4660-878D-A05D897FF89EQ40188974-E14E3102-9A26-40C6-B66E-3836C36CA586Q41906983-9A0BBBCA-9FC6-4BBC-9693-CA60A89B5FCBQ42275612-645CD1B3-36B7-4D19-AFB3-9B4E3B4D6F1AQ42929693-761A9232-D775-4C30-93B7-E4A730A7D3DEQ46486677-CA3B215D-4319-4634-B80E-36D63E63D7A6Q46884185-7E2B0B8E-EC4D-4B32-9C9E-803D8676AF05
P2860
Posaconazole therapy of disseminated phaeohyphomycosis in a murine model.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Posaconazole therapy of disseminated phaeohyphomycosis in a murine model.
@en
type
label
Posaconazole therapy of disseminated phaeohyphomycosis in a murine model.
@en
prefLabel
Posaconazole therapy of disseminated phaeohyphomycosis in a murine model.
@en
P2093
P2860
P1476
Posaconazole therapy of disseminated phaeohyphomycosis in a murine model.
@en
P2093
David Loebenberg
Elizabeth Johnson
John R Graybill
Laura K Najvar
Rosie Bocanegra
P2860
P304
P356
10.1128/AAC.48.6.2288-2291.2004
P407
P577
2004-06-01T00:00:00Z